Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Full data from the Poseidon study confirm the anti-CTLA-4 MAb’s activity; with three chemo combos established, however, will it be enough?
In an unprecedented situation Biogen sought to restrict the use of Aduhelm weeks after the drug’s approval. And the FDA said yes.
But the space, a battle between Opdivo and Keytruda, is becoming extremely complex, and Bristol’s win is not unequivocal.
Lynparza could become the first Parp inhibitor approved for adjuvant use, an Asco late-breaker reveals.